FY 2007 Financial Targets & Goals

1

As of November 30, 2006

Exhibit 99.02

Over FY'07 -

FY'09 3 Year Period:

Fiscal Year 2007

Revenue:

+ 8 -

10%

At or above the high end of long-term goal

EPS

1

:

+ 12 -

15%

2

$3.25 -

$3.40 per share

(includes equity compensation expense)

Operating

FY07 OE

3

growth

Segment

Revenue

Earnings

3

vs. long-term target

Drivers

HSCS -

Pharma

+ 7 -

10%

+ 7 -

10%

In range

*

Strong bulk growth; generic launches; cost control; stable to increasing

EP margins driven by efficient capital usage; impact of Dohmen

acquisition

*

Sell margin pressure; stable to declining operating margins due to sales

mix (driven by lower-margin bulk revenue growth)

HSCS -

Medical

+ 4 -

7%

+ 6 -

9%

In range

*

Strong corporate brand sales growth; cost control; stable to increasing

operating margins; stable EP margins

*

Launch of IPS and customer service consolidations

MPM

+ 6 -

8%

+ 10 -

12%

Above range

*

New contracts; product innovation; international growth; impact of

restructuring and sourcing initiatives; impact of DBI acquisition

CTS

+ 10 -

15%

+ 15 -

20%

Below range

*

Strong product demand for Alaris

and Pyxis

products; new product

launches; continued impact of operational improvements; international

expansion; impact of MedMined

acquisition

*

Increased investment in innovation, quality and service

*

Current estimate of SE pump fix; impact of Care Fusion acquisition

Return on Equity

4

:

15% -

20%

In line with long-term goal

Operating Cash Flow:

> 100% of net earnings

In line with long-term goal

Cash Returned

up to 50% of OCF, via share

-

Quarterly dividend increased 50% to $0.09 per share

to Shareholders

:

repurchase and dividends

2

-

Plan to repurchase $1.5 Billion in FY'07

Credit Rating:

Strong investment grade

Continued progress from BBB

1

Non-GAAP diluted EPS from continuing operations.

2

Excludes the impact of proceeds from the PTS divestiture.

3

Segment operating earnings growth rates represent organic growth only (except as noted).

4

Non-GAAP return on equity.

One Year Targets

Long-Term Financial Goals

CARDINAL HEALTH, INC. AND SUBSIDIARIES

GAAP / NON-GAAP RECONCILIATION

Forward-Looking

Non-GAAP

Financial

Measures

The Company presents non-GAAP diluted EPS from continuing operations and growth rate and non-GAAP return on equity

on a forward-looking basis.  The Company is unable to provide a quantitative reconciliation of these forward-looking non-

GAAP measures to the most comparable forward-looking GAAP measures because the Company cannot reliably forecast

special items and impairment charges and other, which are difficult to predict and estimate and are primarily dependent on

future events.  In addition, the long-term non-GAAP diluted EPS from continuing operations growth rate goal excludes the

impact of the proceeds from the PTS divestiture.  The Company expects to use the proceeds to repurchase shares, which,

depending on the timing of the divestiture, the Company expects should further add materially to fiscal 2008 EPS growth. 

The Company is unable to reliably forecast the proceeds from the

proposed divestiture at this time.  Please note that the

unavailable reconciling items could significantly impact the Company’s future earnings.

DEFINITIONS

GAAP

Operating Cash Flow:

net cash provided by operating activities from continuing operations

Non-GAAP

EP

Margin:

[net

operating

earnings,

after-tax

minus

(tangible

capital

multiplied

by

weighted

average

cost

of

capital)]

divided by revenue 

Non-GAAP Diluted EPS from Continuing Operations:

non-GAAP earnings from continuing operations divided by

diluted weighted average shares outstanding

Non-GAAP

Diluted

EPS

from

Continuing

Operations

Growth

Rate:

(current

period

non-GAAP

diluted

EPS

from

continuing operations minus prior period non-GAAP diluted EPS from continuing operations) divided by prior period

non-GAAP EPS from continuing operations

Non-GAAP

Return

on

Equity:

(annualized

current

period

earnings

from

continuing

operations

plus

special

items

minus

special items tax benefit) divided by average shareholders' equity